| UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
| UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
| UCSD |
|
Mesoblast |
Heart Failure |
The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
No longer active |
|
| UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Active, not recruiting |
|
| UCSF |
|
Jasper Therapeutics |
Severe Combined Immunodeficiency syndrome |
A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID |
Recruiting |
|
| UCSF |
|
Editas Medicine Inc. |
Sickle Cell Disease |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D |
Recruiting |
|
| UCSF |
|
Passage Bio Inc. |
GM1 Gangliosidosis |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant |
Active, not recruiting |
|
| UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
No longer active |
|
| UCSF |
|
Allo Vir, Inc. |
BK Viremia in Kidney Transplant Recipients |
Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients |
No longer active |
|
| UCSF |
|
Poseida Therapeutics, Inc. |
Prostate cancer |
A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
No longer active |
|
| UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
No longer active |
|
| UCSF |
|
CRISPR Therapeutics |
B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL |
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies |
No longer active |
|
| UCSF & UCSD & CIRM |
|
CIRM |
ARDS/COVID |
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) |
No longer active |
|
| UCSF & UC Davis |
|
|
COVID-19/ARDS |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
No longer active |
|
| UCSF |
|
PACT Pharma |
Cancer – Solid Tumor |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors |
No longer active |
|
| UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
| UCSF |
|
Case Western Reserve University |
HIV |
A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) |
No longer active |
|
| UCSF & UC Davis |
|
Poseida Therapeutics, Inc. |
Multiple Myeloma |
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) |
No longer active |
|
| UCSF |
|
Department of Defense |
Acute Respiratory Distress Syndrome (ARDS) |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma |
No longer active |
|
| UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
| UCSF |
|
Seattle Children’s Hospital Foundation |
Cancer - Leukemia |
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia |
No longer active |
|
| UCSF & UCLA |
|
Sangamo Therapeutics |
Blood Disorder - Beta-Thalassemia |
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) |
No longer active |
|
| UCSF |
|
bluebird bio |
Sickle Cell Disease |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease |
No longer active |
|
| UCSF |
|
UCSF |
Blood Disorder - Alpha Thalassemia Major |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
Recruiting |
|
| UCSF and UC Davis |
|
Bioverativ Therapeutics, Inc |
Sickle Cell Disease |
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease |
No longer active |
|
